Brooks Laboratories Share Price

NSE
BROOKS •
BUY

1W Return

1M Return

6M Return

1Y Return

3Y Return

The current prices are delayed, login or Open Demat Account for live prices.
Start SIP in Brooks Laboratories
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
37.74% Fall from 52W High
-11.6
TTM PE Ratio
Negative PE TTM
-17.7
Price to Book Ratio
Above industry Median
5.8
Dividend yield 1yr %
0
TTM PEG Ratio
PEG TTM is less than 1
0.4

Brooks Laboratories Key Financials

View more

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

Brooks Laboratories Quarterly Revenue

Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
38.45 Cr
20.79 Cr
17.93 Cr
17.72 Cr
21.75 Cr

Brooks Laboratories Yearly Revenue

Mar 2024Mar 2023Mar 2022Mar 2021
80.44 Cr
63.41 Cr
91.99 Cr
77.98 Cr

Brooks Laboratories Quarterly Net Profit/Loss

Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
0.7 Cr
0.96 Cr
-0.21 Cr
0.3 Cr
0.58 Cr

Brooks Laboratories Yearly Net Profit/Loss

Mar 2024Mar 2023Mar 2022Mar 2021
1.53 Cr
-27.74 Cr
-19.31 Cr
-19.37 Cr
Brooks Laboratories Result Highlights
  • Brooks Laboratories Ltd reported a 83.7% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 76.0%.

  • Its expenses for the quarter were up by 88.8% QoQ and 77.6% YoY.

  • The net profit increased 15.4% QoQ and increased 17.8% YoY.

  • The earnings per share (EPS) of Brooks Laboratories Ltd declined at 1.8 during Q3FY25.

    Read more

Data Source: BSE, Company announcements

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

Brooks Laboratories shareholding Pattern

Promoter
59.1%
Mutual Funds
3.9%
Domestic Institutions
3.9%
Public
37.1%
Promoter
63.6%
Mutual Funds
3.9%
Domestic Institutions
3.9%
Public
32.5%
Promoter
63.6%
Mutual Funds
3.9%
Domestic Institutions
3.9%
Public
32.6%
Promoter
63.6%
Mutual Funds
3.9%
Domestic Institutions
3.9%
Public
32.6%
Promoter
63.6%
Mutual Funds
3.9%
Domestic Institutions
3.9%
Public
32.6%
Promoter
63.6%
Mutual Funds
2.5%
Domestic Institutions
2.5%
Public
33.9%

Brooks Laboratories Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
1
Bearish Moving Averages
15
5Day EMA
125.20
10Day EMA
131.40
12Day EMA
133.60
20Day EMA
140.80
26Day EMA
144.40
50Day EMA
150.10
100Day EMA
147.40
200Day EMA
137.10
5Day SMA
122.20
10Day SMA
132.20
20Day SMA
143.80
30Day SMA
150.70
50Day SMA
160.10
100Day SMA
150.70
150Day SMA
141.80
200Day SMA
127.80
Delivery & Volume

Delivery & Volume

PeriodCombined Delivery VolumeNSE+BSE Traded Volume
Day Rs
29389 Rs
38896 Rs
Week Rs
23731 Rs
41013 Rs
Month Rs
23084 Rs
31431 Rs
Resistance & Support
124.61
Pivot
Resistance
First Resistance
128.21
Second Resistance
132.61
Third Resistance
136.21
Support
First Support
120.21
Second support
116.61
Third Support
112.21
Relative Strength Index
30.91
Money Flow Index
32.01
MACD
-10.78
MACD Signal
-8.24
Average True Range
10.55
Average Directional Index
29.79
Rate of Change (21)
-25.15
Rate of Change (125)
-3.09

Brooks Laboratories Company background

Founded in: 2002
Brooks Laboratories Limited was incorporated on January 23, 2002. The company was initially promoted for manufacturing latest molecules in Injectables, tablets and dry syrups for the domestic customers. Brooks Laboratories is a pharmaceutical manufacturing company working on contract basis. The company has manufacturing plants at Baddi, Himachal Pradesh and Vadodara, Gujarat. Both the units are cGMP compliant in conformity with national and international standards. The Vadodara facility of the company has been approved by European Medicine agency. The company has a wide range of products catering to critical care segment in Parental Section like Beta Lactam, Cephalosporin General Dry powder Injectables, Ampoules and Liquid vials, Dry Syrups and Tablets etc. Their product portfolio presently comprises of 28 Injectables, 19 Tablets and 2 Dry Syrups which are marketed domestically.The companys manufacturing facilities are designed to manufacture a variety of products in the formulation segment using a combination of processes. At Baddi, they manufacture wide range of products under the formulation segment for various top notch companies of India.The companys major clients are companies like Zydus Cadila, Aristo Pharmaceuticals Pvt Ltd, FDC Ltd, Nectar Lifesciences Ltd, Sanat Products Ltd, Hetero Healthcare Ltd, Medley Pharmaceuticals, Wockhardt Ltd, Parental Drugs, Chanderbhagat Pharma and Alembic Ltd etc. Their major suppliers of raw materials are Rajasthan Antibiotics Ltd, Aurobindo Pharma Ltd, DSM Anti Infectives Ltd and Qilu Pharmaceutical Company Ltd.With roots dating back to 2002, Brooks Laboratories were established with a sole purpose of being a pioneer in the Pharmaceutical industry. Right from its inception, the company has entrenched strong foothold in the Pharmaceutical business and has successfully been a prominent part of Pharmaceutical Formulation Development, Pharmaceutical Production, Pharmaceutical Exports, etc. Starting out as Manufacturer for various Pharmaceutical products in India and abroad, over the years with sheer hard work, the Company earned its valuable name in India and abroad. The Company has a worlds largest dedicated EU certified plant at Vadodara.In the year 2006, the company set up a facility for manufacturing Tablets, Dry Syrup and Injectables, which was supported by a research and development (RD) centre at Baddi, Himachal Pradesh. In May 2006, they started their operations and in June 3, 2006, they commenced commercial production.In October 2006, the company obtained Import license from Drugs Controller General of India under the Drugs Act 1940 and Drugs Rules. In August 2007, they received an AS/NZS ISO 9001:2000 Certificate from SAI Global Certification Services Pty Ltd, Australia. In April 2008, the company took over some of the assets of Brooks Pharmaceuticals, a partnership firm of the promoters, Atul Ranchal Rajesh Mahajan.In April 2010, the manufacturing facility at Baddi was certified as WHO GMP compliant by Department of Health Family Welfare, HP. In July 2010, the company received an ISO 9001:2008 Certificate from UKAS Quality Management, URS IAF.In August 2011, Brooks Laboratories raised money by way of Initial Public Offer Rs. 63 Crore from public. During the financial year ended 31 March 2014, the company operated the Baddi plant at 100% capacity. During the financial year ended 31 March 2015, the company operated the Baddi plant at 100% capacity. During the financial year ended 31 March 2016, the company operated the Baddi plant at 92% capacity.On 7 March 2017, Brooks Laboratories world class dedicated carbapenem facility in Vadodara Plant started manufacturing activity. Brooks Management decided to upgrade the facility in line with cGMP in Baddi plant. Since it was a running unit, the company decided to upgrade the Baddi facility in steps. As a first step, the company upgraded one injectable manufacturing line, which started commercial production in November 2016. The company operated the Baddi plant at 92% capacity during the year under review.The upgradation of injectable line in Baddi facility was carried out for 3 months from June 2017, whereby production in injectable line was affected, upgradation was completed and production started from September onwards in Baddi facility. The company commenced production in August 2017 at Baddi Plant with almost double the capacity of previous line.The Company started production and sales at its manufacturing facility in Vadodara in 201920.
Read More

Brooks Laboratories FAQs

Brooks Laboratories share price is ₹123.82 in NSE and ₹122.8 in BSE as on 20/2/2025 12:00:00 AM. Please be aware that stock prices are subject to continuous fluctuations due to various factors.

Brooks Laboratories share price in the past 1-year return was -3.64. The Brooks Laboratories share hit a 1-year low of Rs. 73.25 and a 1-year high of Rs. 198.86.

The market cap of Brooks Laboratories is Rs. 324.99 Cr. as of 20/2/2025 12:00:00 AM.

The PE ratios of Brooks Laboratories is 183.28 as of 20/2/2025 12:00:00 AM.

The PB ratios of Brooks Laboratories is 4.58 as of 20/2/2025 12:00:00 AM

The Mutual Fund Shareholding in Brooks Laboratories was 9.9% at the end of 20/2/2025 12:00:00 AM.

You can easily buy Brooks Laboratories shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
+91 -

personImage
Open Demat Account
+91 -